Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-610, 355 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PF-610,355 | DRUG | - |
| Salmeterol | DRUG | - |
Inclusion Criteria: * Reversible asthmatic patients (\>15% increase in FEV1 following 200ug salbutamol). * FEV1 greater than or equal to 60% predicted * Stable disease for at least the previous 3 months Exclusion Criteria: * Subjects requiring rescue medication on greater than 2 occasions in the ...
PF-610,355 is an investigational small molecule being studied for the treatment of asthma. It is designed to open the airways in asthmatic patients, according to a completed Phase 2 clinical trial. The drug is being developed by Pfizer, Inc. and is not yet approved for any use.
PF-610,355 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of asthma.
PF-610,355 is in Phase 2 clinical development. A Phase 2 trial has been completed, but the drug remains investigational and has not been approved by regulatory authorities. It is being studied for the treatment of asthma.
PF-610,355 has one completed Phase 2 clinical trial, identified as NCT00468975. The study was a blinded trial examining the ability of PF-610,355 to open the airways in asthmatic patients. It enrolled 42 participants in Germany, Sweden, and the United Kingdom.
PF-610,355 is not FDA approved. It is an investigational drug in Phase 2 clinical development for asthma. A Phase 2 trial has been completed, but the drug has not yet received regulatory approval for any indication.